Spectral ai announces 2024 second quarter financial results

Second quarter revenue totals $7.5 million total enrollment exceeds 85% for burn center pivotal u.s. clinical trial q2 2024 overview research & development revenue of $7.5 million cash position of $6.9 million on track to generate first commercial revenues in the u.k. later this year burn pivotal study nearing completion paving the way for u.s. fda submission in early 2025 announced collaboration with polynovo ltd. providing introduction to australian market continued progress in handheld burn wound diagnostic technology added to russell microcap® index effective july 1, 2024 dallas, aug. 12, 2024 (globe newswire) -- spectral ai, inc. (nasdaq: mdai) (“spectral ai” or the “company”), an artificial intelligence (ai) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended june 30, 2024 (“q2 2024”) and provided an update on its ongoing business activities.
MDAI Ratings Summary
MDAI Quant Ranking